Pharmacy Times offers relevant, clinical information for pharmacists that they can use in their daily practice. These include OTC and Rx product news, disease conditions, patient education guides, drug diversion and abuse, and more.
Issue link: http://pharmacytimes.epubxp.com/i/614520
July 2012 www.PharmacyTimes.com 99 What is different about the patient with cystic fibrosis in terms of life expectancy today compared with 20 years ago? S = Stop, T = Think, A = Assess, R = Review Overview of Cystic Fibrosis Cystic fibrosis (CF) is a chronic, pro- gressive, autosomal recessive disease of exocrine dysfunction that results from a genetic defect in the cystic fibro- sis transmembrane conductance regula- tor (CFTR) gene. 1 The disease currently affects nearly 30,000 Americans, 94% of whom are white and 50.3% of whom are younger than 18 years. 2 Recent advances in CF research have resulted in improve- Current and Emerging Therapeutics in Cystic Fibrosis: Ensuring Continuity of Care within the New Treatment Paradigm CONTINUING EDUCATION December 2015 PharmacyTimes.org 99 Faculty Robert J. Kuhn, BS, PharmD Kentucky Hospital Association Endowed Professor Department of Pharmacy Practice and Science University of Kentucky College of Pharmacy Lexington, Kentucky Elizabeth Autry, PharmD Pediatric Clinical Pharmacist Pediatric Pulmonary and Endocrinology Specialty Pharmacy Services University of Kentucky HealthCare Lexington, Kentucky Disclosures The following contributors have no relevant financial relationships with commercial interests to disclose. Faculty Robert J. Kuhn, BS, PharmD Elizabeth Autry, PharmD Pharmacy Times Continuing Education Planning Staff—David Heckard; Maryjo Dixon, RPh; Dipti Desai, PharmD, RPh; Neelam Davis, PharmD, RPh; Donna Fausak; Tara DeLorenzo; and Nathalie Harden Pharmacy Times Editorial Staff— Kirk McKay An anonymous peer reviewer was part of the content validation and conflict resolution. The peer review- er has no relevant financial relation- ships with commercial interests to disclose. At the completion of this activity, the participant will be able to: 1. Apply knowledge of the changing face of cystic fibrosis (CF), in terms of microbiology and patient demo- graphics, to optimize treatment efficacy, treatment adherence, and overall management of CF 2. Illustrate the pathobiology and pathogenesis of CF and the role of existing therapeutics 3. Examine the importance of airway clearance and the continued role of chronic suppressive antibiotic therapy in treatment of pulmonary exacerbations 4. Analyze the latest clinical data on agents targeting various mutations in CF 5. Explore the potential impact of clini- cal advances in CF on multimodal treatment options and strategies, and communicate effectively with patients and their families about the role of genetic analyses Target audience: Specialty, ambulatory care, and community retail pharmacists Type of activity: Application Release date: December 7, 2015 Expiration date: December 7, 2017 Estimated time to complete activity: 2.0 hours Fee: This lesson is offered for free at www.pharmacytimes.org. EDUCATIONAL OBJECTIVES Pharmacy Times Continuing Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.20 CEUs) under the ACPE universal activity number 0290-0000-15-154-H01-P. The activity is available for CE credit through December 7, 2017. This activity is supported by an educational grant from Vertex Pharmaceuticals, Inc. STAR*